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CHAPTER 1.  GENERAL INTRODUCTION 
Porcine reproductive and respiratory syndrome virus (PRRSV) has been a detriment 
to the pork industry ever since it first emerged in the late 1980s and early 1990s.  As a 
respiratory disease, the virus causes inappetance, lethargy, and increased susceptibility to 
secondary respiratory infections.  Nearly half of the annual economic loss caused by PRRSV 
infection is due to decreased weights of pigs that reach market.  As a reproductive disorder, 
PRRSV causes stillbirths, mummified piglets, and delay in return to estrus.  
Some debate still remains as to the importance of cellular104 versus humoral74 
immune response post PRRSV infection.  Research has shown that virus neutralizing (VN) 
antibodies may play an important role in increased viability at birth 74 and decreased virus 
titers and dissemination within infected pigs and decreased transmission to naïve animals58 
56.  But other researchers have shown that vaccination against PRRSV leading to protection 
involves a cellular immune response, as monitored by IFN-gamma-producing cells104.    
The objectives of the work included in this thesis were to produce high titers of VN 
antibodies to PRRSV and subsequently to passively administer these antibodies to provide 
protection against challenge with both homologous and heterologous strains of the PRRSV.  
A literature review follows providing a brief overview of PRRSV including passive 
immunization of pigs with antibodies against PRRSV.  Chapters 2 and 3 are written in 
journal article format, followed by the author’s conclusions. 
Literature Review: Porcine reproductive and respiratory syndrome virus 
History 
A destructive virus struck the pork industry in North America in 1987 25 50 and in 
Europe in 1990 93 and quickly became the most economically significant disease in the 
industry.  Unidentified at the time, Porcine Reproductive and Respiratory Syndrome (PRRS) 
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was known by many names, such as “porcine epidemic abortion and respiratory syndrome”, 
and Blue Ear disease in Europe, while in the United States, it was being called Mystery 
Swine Disease, and Swine Infertility and Respiratory syndrome (SIRS)103.  The disease was 
initially observed to cause anorexia, reproductive disorders, stillbirths, mummified, and weak 
piglets and abortion in pregnant sows.  On occasion, affected pigs were observed to have 
blue ears.  In piglets, the disease caused respiratory difficulty, ataxia, muscle tremors, and 
often death.   
Initially the etiologic agent of this disease was unknown.  Wensvoort et al. first 
isolated a virus from infected sows on porcine alveolar macrophages, and designated it 
Lelystad Virus (LV)93.  Collins et al. isolated the North American strain of PRRSV, VR 
2332, which became the North American prototype strain 25.  Both LV and VR 2332 were 
confirmed to be the etiologic agent of the disease when Koch’s postulates were completed in 
1991 by isolating the virus from infected sows, re-infecting pregnant sows, and finally 
isolating it from piglets farrowed from the re-infected sows  20 85.  The disease was also 
reproduced in gnotobiotic pigs that had been exposed to tissue homogenates from infected 
animals 25 82.   After being confirmed as the etiologic agent, the virus became widely known 
as porcine reproductive and respiratory syndrome virus (PRRSV).   
Characterization and classification 
In 1992, Benfield et al. 13 and Wensvoort et al. 92 showed the virus to be enveloped by 
pretreating the virus with chloroform, harvesting the aqueous phase, and checking infectivity.  
The virus is spherical in shape with an icosahedral nucleocapsid 13 30 62.  Morphological 
similarities between PRRSV and equine arteritis virus (EAV) were found in diameter of the 
virus, 40-60 nm, and size of nucleocapsid core, 25-35 nm 13 92. Dea et al. 30 showed that viral 
antigens could be found in infected cell cytoplasm by 6 hours post infection (hpi).  The virus 
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also was shown to bud at the smooth endoplasmic reticulum (ER) and accumulate in the 
Golgi vesicles or in the ER lumen, causing the ER to enlarge.   
Being a small enveloped single-stranded positive sense RNA virus, PRRSV was 
classified in the genus Arterivirus, family Arteriviridae, order Nidovirales  67.  The genus 
Arterivirus includes EAV, simian hemorrhagic fever virus (SHFV), and lactate-
dehydrogenase elevating virus (LDV) 26 80.  The genome was determined to be a linear 
single-strand positive sense of polyadenylated RNA and approximately 15.1 kilobases in size 
67.  The genome consists of at least eight open reading frames (ORFs) 3 67.  ORF 1a and 1b 
are involved in viral genome replication and mRNA transcription, ORFs 2-5 encode the 
membrane proteins, ORF 6 encodes the matrix protein  and ORF 7 encodes the 
nucleopcapsid  protein61 68.  These proteins are translated from 6 nested subgenomic RNAs 
with a common leader sequence and are produced through discontinuous transcription 64 87.   
All of the PRRSV structural and non-structural proteins have been identified.  The 
nucleopcapsid protein (N) is not glycosylated, has a molecular weight of 15 kiloDaltons 
(kDa) and forms a homodimer 46.  The matrix protein (M) has a molecular weight of 19 kDa 
and forms a heterodimer via disulfide linking to envelope protein GP5 60, similar to EAV 27.  
GP5 has N-linked glycans, but varies from strain to strain, varying the molecular weight 
between 25-28 kDa 46.  ORF 2, 3, and 4 encode minor N-glycosylated structural proteins 
GP2, GP3, and GP4, respectively 88 69.  
There is a large range of antigenic and genetic variation 12 78 100 between viral strains, 
especially North American strains versus European strains 28 71.  The N protein, encoded by 
ORF 7 of LV, shared 58% amino acid identity when compared with a North American strain, 
VR 2385 (ATCC) 29 64.  In that same study by Meng et al., the two viruses showed 54% 
amino acid identity in ORF 5 and 78% in ORF 6.  A study of 15 Canadian strains, the VR 
2332 attenuated vaccine strain and 2 European strains showed different reactivities with 
monoclonal antibodies against the N and M proteins 28.     
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Disease and Pathogenesis 
PRRS causes the pork industry a loss of between $560 and $761 million annually, 
$201.34-$244.53 million of which are lost in the nursery phase alone 48 72.  Disease induced 
by PRRS virus ranges in clinical signs from anorexia, lethargy, dyspnea and reproductive 
complications such as still-born, mummified, and aborted fetuses.   
Initial clinical signs in breeding animals will start with lethargy, fever, and reduced 
feed consumption.  Gilts and sows in an infected herd may display decreased conception 
rates and a delay in return to heat 50.  Late-term reproductive failure starts to occur within two 
weeks of acute illness in pregnant animals 11 20.  Live piglets, whether born normal or weak, 
will have up to 60% preweaning mortality.  Suckling pigs often show signs of lethargy, 
starvation, failure to thrive, splay-legs, and respiratory distress such as rapid and labored 
breathing 50.  Nursery piglets also may be off feed but more frequently display more 
respiratory problems in addition to anorexia.  This inappetance causes a reduction and 
variability in weight gain.  Another severe problem with PRRSV infection is the added 
complication of secondary bacterial infections 83. 
Anorexia is an important clinical sign seen with PRRS virus infection in grow-finish 
animals and the virus will cycle through a herd with approximately 20% of the herd affected 
at a time, known as “rolling inappetance” 21.  Recent data has shown that PRRSV positive 
pigs have a significant reduction in weight gain that is not made up prior to going to 
slaughter 72.  Some grow-finish animals will experience increased respiration rate and 
lethargy 50.  Once pigs are infected and become viremic, viremia can last up to 4-6 weeks in 
suckling, weanling, and grow-finish pigs 65.  PRRSV has been found to persist in weaned 
pigs for up to 157 days post infection (dpi) 96 and in adult sows for up to 86 dpi 14.  One study 
even detected PRRSV RNA in tonsil samples up to 225 dpi 94. 
Transmission of PRRSV occurs via vertical 19 20 and horizontal transmission 14 22 95 96 
99.  Aerosol transmission of pigs in close contact, but not necessarily direct nose-to-nose 
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contact, is thought to be a major factor in natural transmission 86 95.  Infection can occur via 
oral and intranasal exposure with 1 x 105.3 50% tissue culture infective dose (TCID50) and 
104.0 TCID50  respectively 43.  Intramuscular exposure of animals to 1 x 102.2 TCID50 has been 
shown to result in infection 43.  Another important method of transmission is the introduction 
of PRRSV positive pigs or semen into naïve herds22 88  99 102.  Animals can become infected 
via PRRSV positive semen at a minimum viral concentration of 2 x 103 TCID50/ml 10.  It has 
been shown that mosquitoes (Aedes vexans) can serve as mechanical vectors of PRRSV, but 
it has not been determined if they can serve as biological vectors or the rate at which this 
transmission method actually occurs 76.   
The main factor of viral pathogenesis is the in vivo tropism for macrophages, 
especially porcine alveolar macrophages (PAMs).  Two receptors, porcine sialoadhesin and 
heparan sulphate, on PAMs have been identified as being used by both American and 
European strains of PRRSV 34 90 but the virus attaches to each receptor via a different 
mechanism 31.  It has also been shown that porcine sialoadhesin alone is capable enabling 
viral attachment and internalization, while heparan sulphate can not mediate nor is required 
for virus internalization 31.  The presence of sialic acid on the surface of the PRRS virion is 
necessary for the attachment to PAMs 33.  Once the virus has bound to a receptor, receptor-
mediated endocytosis occurs via clathrin-coated pit invagination 90.  The cell receptors are 
bound by the M protein on the virus either by itself or in heterodimer formation with GP5 34.   
Immune Response 
Lack of understanding of the immune response in a natural PRRSV infection still 
prevents us from developing efficacious and effective prevention methods.  The virus infects 
primarily alveolar macrophages and other tissue macrophages 82.  The virus can be found at 
high levels in tissues (especially lymphoid tissue) and the pig may remain viremic for up to 4 
weeks 39 40 59 100.  Most pigs recover from infection within several months of the initial 
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infection 94.  Persistent infection can occur in which virus remains in the tonsil and lymph 
nodes and can be shed intermittently 2 84 96 100.   
The cell-mediated immune (CMI) response that occurs in natural PRRSV infection 
has been studied and analyzed.  It has been shown that the initial cellular response occurs 
approximately 4 weeks post infection, when viremia has already been cleared, and continues 
for at least 11 weeks 9 57, in which CD4+ T cells are the main effector cells 9.  It was shown 
that CD8+ T cells proliferated 35, some of which were CD4+CD8+ double positive cells 57.  
These cells have been shown to have a role as memory T-helper cells 45.  Depletion of CD8+ 
T-cells by mAb treatment of pigs during the initial stages of PRRSV infection did not show 
any effect on severity of disease or on level of viremia 56. 
Lopez Fuertes et al.57 studied cytokine expression in vitro by harvesting peripheral 
blood mononuclear cells (PBMC) from recovered animals and stimulating the PBMC with 
PRRSV.  It was shown that in vitro IL-2 and IFN-γ genes were expressed 57.  Another study 
showed IL-10 and IL-12 expression in the lungs of PRRSV infected pigs 23.  Others have 
found PRRSV to elicit weaker and delayed IFN-γ expression than pseudorabies virus 63.  
Innate cytokine production was shown to be weakly stimulated by PRRSV, especially when 
compared with responses to other swine respiratory viruses 1 89.  IFN-α production is not 
induced following PRRSV infection, which may also reduce an effective immune response 1 
89.  It has also been shown that using IL-12 as an adjuvant with the PRRSV modified live 
vaccine (MLV) increases the IFN-γ response 16.  IL-12 has been shown to be capable of 
stimulating PAMs to produce IFN-γ 15 in addition to that produced by T-cells and NK cells.   
The first humoral response to occur is the production of anti-N antibodies 55, which 
are not virus neutralizing (VN) antibodies and do not aid in viral clearance 101.  This initial 
antibody spike occurs 7-9 days post infection (pi) and VN antibodies finally start to appear 
about 4 weeks pi  1 52 55 101.  VN antibodies have been shown to have a protective role in 
reduction and prevention of viremia 74 88, but viremia has been shown to occur in the 
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presence of VN antibodies 96.  Antibodies against GP5 have been found to be more 
neutralizing than anti-GP4 antibodies and are the most effective VN antibodies 91.  This is 
supported by in vitro studies that have shown VN antibodies able to reduce PRRSV 
attachment to macrophages and inhibit virus internalization, since GP5 is involved in viral 
attachment.  But attachment and internalization are only inhibited when homologous PRRSV 
strains and VN antibodies are used 32.   
The neutralizing epitope of GP5 has been identified as amino acids 37-45 75 81 located 
at the N-terminal and is called epitope B.  This has been shown to be the region responsible 
for the neutralizing activity of the VN antibodies and is in the same location in the European 
LV strain 79 97.  VN antibodies from EAV-infected and LDV-infected animals are against the 
protein homologous to the PRRSV GP5, GL and VP-3P respectively18.  Each of these viruses 
has a neutralizing epitope in the same general location in their homologues of GP5 18 53.    
Ostrowski et al.75 identified a region of the PRRSV GP5 that was immunodominant, 
which they called epitope A.  Non-neutralizing antibodies are produced to epitope A and are 
produced early in infection 75.  It has been hypothesized that epitope A functions as a “decoy 
epitope”, and has been hypothesized to decrease the immune response to a nearby 
neutralizing epitope, epitope B59.  When neutralizing titers become detectable, antibodies 
recognize epitope B and thus demonstrate neutralizing ability.  It has been hypothesized that 
as epitope A acts as a decoy epitope, it allows the virus to evade a stronger humoral immune 
response by inducing non-neutralizing antibodies to be the initial antibodies produced.  The 
immunogenicity of GP5 may also be affected by N-linked glycans 37 that are post-
transcriptionally added to the protein.  These workers suggested that the varying GP5 glycans 
of different PRRSV strains affect the immune response induced in the pig, altering the rate at 
which VN antibodies are produced and the titer that these VN antibodies reach. 
Passive maternal antibody has been shown to decrease clinical signs, occurrence of 
viremia, and reduce weight loss 40 70 in piglets that received maternal antibody and has been 
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shown to increase the minimum challenge dose for infection with VR-2332 70.  VN 
antibodies can be increased in sows with prior PRRSV exposure by administering a killed 
PRRSV vaccine prior to farrowing 73.   
Other arteriviruses have been shown to require VN antibodies for preventing 
infection.  EAV in horses is prevented by vaccination that induces complement-fixing and 
VN antibodies 6 and passive immunization via antibodies in colostrum has protected against 
clinical EVA 44.  Alphavirus replicon particle vaccine which expressed EAV M-GP5 
heterodimer has been shown to provide protection against EAV 4.  LDV infection is also 
prevented in mice by transfer of VN antibodies 17. 
Recent data has shown that immunization with GP5 and M proteins either 
individually or together (not heterodimerized) provide some protection against virulent 
PRRSV challenge 8 47 51 77 and are more effective than DNA vaccines using other PRRSV 
ORFs 7.  A virus replicon particle expressing the EAV major envelope proteins in mice was 
shown to require the heterodimer formation for VN antibodies to be produced 5. 
Passive immunization has been shown to be protective against PRRSV infection 74.  
Osorio et al. produced immune plasma with VN immunoglobulin (Ig) against PRRSV, 
concentrated the plasma, and injected it into the peritoneal cavity of pregnant gilts in one 
experimental group.  The other experimental group received antibody to psuedorabies virus 
(PRV Ig) as a control.  No clinical signs were exhibited in the group that received PRRSV Ig, 
in contrast to the sows in the PRV Ig group that showed lethargy, inappetance, and mild 
fever.  Offspring viability at weaning was stastically increased from 4% in the PRV Ig group 
to 95% in the PRRSV Ig group.  In addition, vertical transmission was prevented in the 
PRRSV Ig group as shown by no live virus in any of the offspring.   
Another passive immunization study performed by Lopez et al.58 showed that 
administering VN antibodies against PRRSV to piglets protected against infection.  When 
VN titers reached 1:8 or greater there was a reduction in rectal temperatures and viral load in 
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tissues, and a faster clearance of viremia.  Although some immunized animals were not 
viremic, transmission to sentinel pigs still occurred as well as dissemination of PRRSV to 
tissues in challenged VN antibody immunized pigs.  A VN titer of 1:32 after passive 
immunization induced sterilizing immunity in 50% of the animals immunized.   
Other methods of producing passive antibodies have also been examined.  
Specifically, avian immunogluobulin (IgY) against PRRSV was given to naïve gilts prior to 
introduction to a herd 39.  Although there was a reduction in viral load in immunized gilts, 
there was not a statistically significant difference in clinical symptoms and reproductive 
disorders.   
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CHAPTER 2.  PRODUCTION OF IMMUNE PLASMA 
AND THE DECAY OF ANTIBODY TO PRRSV IN PIGS 
PASSIVELY IMMUNIZED 
Introduction 
Neutralizing antibodies against PRRSV have been shown to have a role in protection 
against PRRSV infection 74.  Recently, it was reported that infection of pigs with strain 
HLV013 rapidly induced high neutralizing antibody titer 37 .  In a previous study, it was  
observed that when a group of pigs was accidentally infected with two unrelated wild 
mutants of PRRSV that a rise in neutralizing antibodies to heterologous strains occurred 
(Hocker, Erdman, Harris Unpublished data, 2004).  We hypothesized that hyperimmunizing 
naïve gilts with multiple strains of PRRSV, with varying levels of glycosylation, would yield 
both high homologous and heterologous neutralizing antibody titers.   
The following reports the results of hyperimmunization of naïve gilts with various 
strains of PRRSV.  Also reported are the titers of antibody in pigs passively immunized with 
plasma derived from this hyperimmunization process.  An antibody decay rate was calculated 
for each pig passively immunized with immune plasma.  
Materials and methods 
Viral propagation 
Three field strains of PRRSV were propagated for the production of immune plasma: 
HLV013, HLV093, and HLV096.  Each strain was grown on MARC-145 cells in a 75 cm2 
flask, containing Dulbecco’s Minimal Essential Mediaa (DMEM) with 10% Fetal Calf 
Serum, 1% L-glutamine, and 0.2mg/ml gentimicin.  Cells were allowed to grow for 3 days 
                                                 
a Invitrogen Corporation, Carlsbad, CA. 
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until a confluent monolayer was present.  Media was removed from the confluent monolayer 
and 1 ml of a stock virus was added to the monolayer.  The virus and monolayer were 
incubated at 37°C for 1 hour.  Twenty ml of fresh, cold DMEM was added to the flask and 
incubated until 90-95% cytopathic effect (CPE) was reached. At desired CPE, the neck of the 
flask was wrapped in parafilm and frozen at -80°C overnight.  The flask was thawed in a 
37°C water bath.  Once thawed, the virus-cell suspension was transferred to a 50 ml tube and 
centrifuged at 4°C for 15 minutes at 377 x g.  The supernatant was removed and aliquoted 
appropriately for use as live virus in the hyperimmunization process. 
Virus titration 
Each virus grown for infection was titrated by virus isolation as described previously 
49.  Marc-145 cells were grown in 96-well flat-bottom plates for 3 days until monolayers 
were confluent.  A 100 μl aliquot of each virus was serially diluted in 10-fold dilutions out to 
10-6 in 900 μl of DMEM with 4% fetal calf serum, 200 μg/ml gentimicin, and 2.5 μg/ml 
Fungizoneb.  Four replicates of each dilution were set up and incubated at 37°C with 5% CO2 
for 8 days and examined for cytopathic effect (CPE).  A direct fluorescent antibody assay 
was also used, in which virus was incubated on cells for 3 days, fixed with cold 70% 
acetone/30% methanol.  A FITC-conjugated monoclonal antibody against the PRRSV 
nucleocapsid protein, SDOW-17Fc, was diluted 1:250 in 1xPBS and 60 μl was aliquoted to 
each well, and incubated for 45 minutes at 37°C.  Antibody was removed and wells were 
washed 3 times with 200 μl 1xPBS. Using an inverted fluorescent microscope, wells were 
examined for fluorescence.  Viral titers were calculated using the Reed-Muench calculation.   
Hyperimmunization of naïve gilts 
                                                 
b Invitrogen Corporation, Carlsbad, CA. 
c Rural Technologies Inc., Brookings, SD 
 
 12
Thirty-six PRRSV negative gilts were received from a specific-pathogen free (SPF) 
herd and randomized into 5 groups using SAS statistical randomization program.  All 
animals were tested by IDEXX HerdChek® ELISAd for antibodies against PRRSV 
nucleocapsid.  Groups 1-4 were maintained in 2 rooms, 4 pens, while group 5 was 
maintained in 2 separate rooms.  The pigs in groups 1-4 were hyperimmunized via infection 
with different strains of live PRRSV (titers ranging from 7.26 x 102 TCID50/ml to 2.28 x 105 
TCID50/ml).  Group 5 did not receive any live PRRSV at any time.  Plasma was harvested at 
different time points from all groups, described in days post first infection (dpi 1), days post 
second infection (dpi 2), and days post third infection (dpi 3).  Experimental groups were 
divided as shown in Table 1.   
 
Treatment 
group 
Number of 
pigs 
PRRSV strain and 
number of 
administrations 
PRRSV titer 
(CCID50/ml) 
Necropsy 
1 4 HLV013 x 1 2.28 x 106 52 dpi 1 
2 8 HLV013 x 2 4.74 x 105 29 dpi 2, 86 dpi 1 
3 4 HLV013 x 1 + 
HLV093 x1 
 
7.26 x 102
32 dpi 2, 112 dpi 
1 
4 4 HLV013 x 1 + 
HLV093 x 1 + 
HLV096 x 1 
 
 
1.39 x 106
22 dpi 3, 55 dpi 
2, 135 dpi 1 
4 22 dpi 1  
1 70 dpi 1 
3 73 dpi 1 
6 78 dpi 1 
5 
4 
None None 
100 dpi 1 
Table 1.  Experimental design for production of immune plasma.  Gilts were divided into 5 
treatment groups, each group receiving a different hyperimmunization schedule, number, and 
sequence of PRRSV strains.   
*Animals from group 5 were necropsied at different time points post first immunization of 
groups 1-4 due to housing restrictions. 
                                                 
d IDEXX Labs, Portland, ME. 
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All pigs in groups 1-4 were infected with HLV013 at 62 days of age (day 0).  Live 
virus was administered intramuscularly (IM) with 2 ml of virus at a titer of 2.28 x 106 
TCID50/ml.  Antibody response was monitored by bleeding all pigs and submitting sera for 
IDEXX ELISA.  All pigs were bled at 22 and 42 dpi 1, after which each group was bled 
intermittently at different times (Table 2). Group 1 was only infected with HLV013 at day 0.  
Group 2 was infected with HLV013 at 0 dpi 1 and infected with 2 ml of HLV013 (4.74 x 105 
TCID50/ml) at 57 dpi 1.  Group 3 was infected with HLV013 at day 0, and infected with 2 ml 
of HLV093 (7.26 x 102 TCID50/ml) at 80 dpi 1.  Group 4 was infected with HLV013 at day 
0, infected with 2 ml of HLV093 (7.26 x 102 TCID50/ml) at 80 dpi 1, and infected with 2 ml 
of HLV096 (1.39 x 106 TCID50/ml) at 113 dpi (33 dpi 2).   
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At 52 days post infection one (dpi 1), 4 pigs were necropsied and plasma 
harvested, terminating treatment group 1.  The remaining three treatment groups were 
infected and necropsied as follows: group 2 was infected with HLV013 at 57 dpi 1, and 
necropsied 86 dpi 1(29 dpi 2); group 3 was infected with HLV093 80 dpi 1, and 
necropsied 112 dpi 1 (32 dpi 2); group 4 was infected with HLV093 80 dpi 1, infected 
with HLV096 113 dpi 1 (33 dpi 2), and necropsied at 135 dpi 1 (55 dpi 2, 22 dpi 3).   
Plasma was submitted to the Iowa State University Veterinary diagnostic 
laboratory where the PRRS IDEXX HerdChek® ELISA was performed.  Fluorescent 
focus neutralization (FFN) assay was performed by the South Dakota State University 
Animal Disease Research and Diagnostic Laboratory to determine the level of VN 
antibodies present in serum as described previously 98.  Briefly, serum was diluted in 
Eagle’s minimal essential medium supplemented with 2% horse serum.  Virus was added 
to each sample and allowed to incubate at 37°C for 1 hour.  Each dilution was then 
transferred to a 96-well plate in which confluent monolayers of MARC-145 cells were 
grown.  Plates were fixed with 80% acetone after 24 hours.  FITC conjugated SDOW-17 
was incubated in wells for 1 hour to detect infected cells.  A dilution was considered 
positive when there was a 90% or greater reduction in the number of fluorescent foci.  
Samples were titrated to extinction unless the sample volume was not sufficient.  Strains 
used in FFN tests were SDSU23983, VR-2332, HLV013, HLV092, HLV096, ISU-P, 
Prime Pac, SD01-08 (European-like), and Lelystad Virus (LV) (see Appendix for 
sequence homology). 
Plasma Harvest 
In order to harvest the largest volume of plasma, pigs were intravenously 
administered Telazol 100 mg/ml(Tiletamine HCl and Zolazepam HCl), with  Ketamine 
(100 mg/ml) and Xylazine (100 mg/ml) and exsanguinated to collect all blood possible.  
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Blood was collected in sterile glass beakers with sodium citrate to prevent clotting.  
Blood was centrifuged at 2054 x g and plasma was pipetted off and frozen at -20°C.  An 
aliquot of plasma collected at selected intervals and necropsy was submitted to South 
Dakota State University Animal Disease Research and Diagnostic Laboratory for 
fluorescent focus neutralization (FFN) assay.   
Antibody rate of decay study 
To determine the rate at which passively administered antibody would decay post 
injection, a non-challenge study was conducted in which pigs were passively immunized 
with immune plasma into the peritoneal cavity and bled frequently.  Two pigs were 
passively immunized with 10 ml per kilogram (kg) of body weight of monovalent 
immune plasma from pig 370 of treatment group 2 (see above) with an FFN titer of 1:128 
against HLV013 (50 ml total administered).  Each pig was bled at 0, 4, 8, 12, 24, 48, 72, 
96, 120, 168, 240, and 312 hours post immunization (hpi).  FFN was run on serum from 
each time point to show the antibody rate of decay (excluding pig 168 at 120 and 168 
hpi).    In order to calculate the decay curve, the change in antibody titer over time was 
divided by the duration of the study38, i.e. ((peak titer)-(titer at 13 days))/(13 days-(days 
at peak titer)).  The resulting rate of antibody decay is described in VN titer units per day.   
Antibody maintenance curve 
In addition to the decay curve, another passive immunization study was done to 
determine the level at which virus-neutralizing antibody could be maintained by repeated 
immunizations.  Two pigs were passively immunized by subcutaneous injections of 1.25 
ml of immune plasma per kg of body weight.  The immunization was repeated at 48 
hours and again at 96 hours, for a total of 3 injections.  Each pig was bled at 0, 12, 24, 48, 
96, and 144 hpi.  FFN was run on serum from each time point to demonstrate the 
maintenance of antibody (excluding pig 166 at 12 hpi).   
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Results 
Upon arrival, all pigs were PRRSV negative, as determined by assay for 
nucleocapsid antibody (IDEXX ELISA) with Sample/Positive (S/P) ratios ranging from 
0.000 to 0.112.  All pigs were tested again immediately prior to the first infection and 
again were negative for PRRSV with ELISA S/P ratios ranging from 0.000 to 0.046.  By 
22 dpi, 90% pigs in groups 1-4 had seroconverted as assayed on the IDEXX ELISA with 
S/P ratios ranging from 0.407 to 2.206 (data not shown) whereas group 5 pigs were 
negative when tested at 17 dpi of groups 1-4 (S/P ratios ranging from 0.00 to 0.04).  At 
22 dpi, all 4 pigs in treatment group 1 had positive FFN titers ranging from 1:32 to 1:512 
against the homologous strain HLV013, but only 1 pig had a titer, which was very low, 
against heterologous strains (Table 3).  By 42 dpi, homologous titers ranged between 
1:128 and 1:512.  Each pig had very low positive titers to at least 1 heterologous strain.  
FFN titer to HLV013 did not increase by necropsy at 52 dpi.   
Treatment group 2 had FFN titers of at least 1:16 by 22 dpi 1 against the infection 
strain, but no positive FFN titers against heterologous strains (Table 4).  At 42 dpi 1, FFN 
titers were between 1:32 and 1:128 against HLV013.  There was no increase in FFN titer 
between 64 and 71 dpi 1 (7 and 14 dpi 2). 
At 22 dpi, treatment group 3 had FFN titers ranging from 1:64 to >1: 512 against 
HLV013, but no positive titers against heterologous strains until 42 dpi (Table 5).  At 94 
dpi 1 (14 dpi 2), titers to heterologous strains increased.  For example, titers against 
SD23983 at 42 dpi ranged from 1:4 to 1:32 and at 94 dpi ranged from 1:128 to 1:256.  By 
necropsy at 112 dpi 1 (32 dpi 2), all heterologous strain titers either remained the same or 
decreased from those at 94 dpi 1.   
Treatment group 4 had no positive titers against heterologous strains at 22 dpi 1, 
but homologous titers ranged from 1:256 to >1:512 (Table 6).  By 42 dpi 1, two pigs had 
positive titers against heterologous strains.  By 94 dpi 1 (14 dpi 2), homologous titers 
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ranged from 1:512 to 1:4096.  By necropsy at 135 dpi 1 (55 dpi 2, 22 dpi 3), titers against 
all strains were either the same or decreased from that at 94 dpi 1.   
The literature states that VN antibody is produced approximately two weeks after 
nucleocapsid antibody, which usually is detected between 7 and 9 dpi 52 98.  Since group 5 
did not have nucleocapsid antibody at any time as determined by ELISA (data not 
shown), it was assumed that they did not have VN antibodies.  Sera from 4 pigs in group 
5 were assayed by FFN to confirm the pigs were negative by another assay, and were 
negative for VN antibodies (see appendix).  At each necropsy of group 5 pigs, all S/P 
ratios for nucleocapsid antibody remained below the cutoff of 0.4, indicating all of the 
group 5 pigs remained negative throughout the study. 
In the antibody rate of decay study, VN titers of immunized pigs were detected by 
4 hours post immunization (hpi) (Figure 1). For pig 1099, the peak VN titer was 1:64 at 
48 hpi and the final VN titer was 1:16 at 312 hpi (13 days).  The rate of VN antibody 
decay for pig 1099 was calculated to be -4.36 VN titer units/day, calculated from peak to 
end of study.  For pig 168, the peak VN titer was 1:32 at 12 hpi and the final titer was 
1:16 at 312 hpi.  The rate of VN antibody decay for pig 168 was -1.45 VN titer units/day, 
calculated from peak to end of study.   VN antibody titers did not drop below 1:16 at any 
time point during the study for either pig.    
In the antibody maintenance study, pig 165 had a positive titer at 12 hpi (Figure 
2).  A blood sample could not be taken from pig 166 at 12 hpi.  By 24 hpi, both pigs had 
positive FFN titers and maintained positive titers for the duration of the study, 144 hpi.  
Pig 165 had a peak titer of 1:32 at 144 hpi.  Pig 166 had a peak titer of 1:16 at 48 hpi that 
was maintained until 144 hpi.  
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Table 7.  Range and geometric mean VN titers in serum were determined against 
different PRRSV strains at necropsy.   
Treatment 
group 
Range of VN 
titers against 
HLV013 
Geometric 
mean VN titer 
against 
HLV013 
Range of VN 
titers against 
ISU-P 
Geometric 
mean VN titer 
against ISU-P 
1 1:64-1:256 1:128 1:64-1:256 1:152 
2 1: 64-1:256 1:140 1:32-1:256 1:90 
3 1:1024-1:2048 1:1218 1:512-1:1024 1:861 
4 1:64-1:1024 1:362 1:256-1:2048 1:512 
5 <1:4 <1:4 ND* ND* 
*Not Determined 
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Figure 1.  Antibody rate of decay.  Neutralizing antibody titers in serum were determined 
by FFN against HLV013.  Each pig was immunized once with 10 ml/kg immune plasma. 
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Figure 2.  Antibody maintenance curve.  Neutralizing antibody titers in serum were 
determined by FFN against HLV013.  Both pigs each received 3 intraperitoneal 
injections of 1.25ml/kg immune plasma.  
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Discussion 
Infection of gilts with strain HLV013 (Groups 1 and 2) resulted in high 
neutralizing antibody titer to the homologous strain as previously reported 37.  FFN 
results with this antisera against heterologous strains indicated cross reactivity with ISU-
P a strain with only 93 % GP5 sequence homology but with identical glycosylation 
pattern in the ectodomain portion of GP5 (see appendix).  Of the other strains tested by 
FFN against Groups 1 and 2 plasma, strains HLV096 and PrimePak showed some 
comparable level of heterologous neutralizing cross reactivity (Tables 3 and 4).   
The infection of gilts with two different strains (Group 2) or with three different 
strains (Group 3) of PRRSV resulted in high titer neutralizing antibodies to all North 
American strains evaluated but no cross reactivity to the European strains (Tables 5 and 
6).  It is interesting to note that strain HLV093 (used as the second infecting strain in both 
Groups 3 and 4) has a unique glycosylation pattern as compared to all other strains.  
Strain HLV093 lacks a glycan at AA position 44 which is centered in the neutralizing 
epitope region of GP5 75 81.  It is tempting to speculate that the absence of this glycan 
allows for the inducement of cross reacting antibodies to the other NA strains tested by 
FFN.  However, further work is necessary to confirm this statement. 
Osorio used 6 different strains of PRRSV over a 7 month to 14 month period in 
production of their hyperimmune serum74.  Our treatment group 2 was infected with only 
1 PRRSV strain (HLV013) and produced similar titers in just under 3 months.       
 Due to constraints of time, money, and facility availability, we were unable to 
maintain all 4 treatment groups for the entire duration of the study, thus making 
comparison of the 4 groups difficult.  FFN titers of treatment group 4 were much higher 
than those produced in group 1 and 2, possibly due to infections with 3 PRRSV strains or 
due to length of time post infection.   
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FFN titers of group 3 were similar to the titers seen in group 4 at each groups 
necropsy.  It can not be determined how the third infection of group 4 affected the titers.  
Because groups 3 and 4 were treated identically until 112 dpi, and group 4 was infected 
again at 113 dpi, it would have been extremely informative to maintain group 3 and have 
a final comparison of both groups at 135 dpi.  Because group 3 was terminated 23 days 
prior to group 4, it is difficult to say if the titers of group 4 were due to a third infection or 
due to duration of time post infection. 
If we had the opportunity to repeat this experiment to improve the clarity of the 
results, each treatment group would be given their subsequent immunizations at the same 
time points and all treatment groups would be maintained for the same duration and 
blood samples taken at the same time points so that all titers could be compared directly 
to determine if increase in number of strains used and the pattern of strains affected the 
level of VN antibodies.       
 Rate of antibody decay for each pig was calculated from peak to end of study.  
The antibody rate of decay was calculated to be -4.36 VN titer units/day for pig 1099 and 
-1.45 VN titer units/day for pig 168.  As is shown in Figure 1, at 240 hpi (10 days) pig 
1099 had a titer of 1:32, which represents a 2-fold increase in titer from the previous time 
point.  The VN titer returns to 1:16 at 312 hpi.  This increase/decrease illustrates the 
assay variability.  Therefore, if the titer at 240 hpi was actually 1:16, the decay rate could 
be calculated as -9.6 VN titer units/day if calculated from peak to date of lowest titer.  
This same logic can also be applied to pig 168, and, if calculated from 12 hpi to 240 hpi, 
results in a rate of -1.68 VN titer units/day.  The two pigs appear to have significantly 
different rates of antibody decay, which is not likely.  If there is a 2-fold variability in the 
FFN assay, and pig 168 actually had a peak FFN titer of 1:64 at 48 hpi, just as pig 1099, 
this would result in a decay rate of -4.36 VN titer units/day, identical to that calculated 
for pig 1099.  Importantly, after a more rapid initial rate of decay through 5 days post 
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peak, VN antibody levels in pig 1099 remain relatively stable for the next 6 days.  The 
VN titers of pig 168 were also maintained at ≥1:16 for 308 hpi.  This might suggest that 
neutralizing levels of antibodies can be maintained for a substantially long period, which 
would be interesting to determine exactly how long they are detected after passive 
immunization.  A follow up experiment with a larger number of animals would be 
beneficial to determine statistically relevant decay rate.  A VN titer of 1:16 has 
previously been reported as protective against PRRSV infection 74 58.  That both pigs 
maintained VN titers ≥1:16 through 312 hpi shows that the VN antibody titers achieved 
in these passively immunized pigs were sustained at protective levels and should prevent 
infection in a PRRSV exposure.   
The antibody maintenance study followed to determine if smaller doses of 
immune plasma given over a period of time by subcutaneous injection could maintain 
VN antibody levels over a longer period of time.  The study did show that VN levels 
were maintained similar to those in the antibody decay curve, even though the plasma 
was given through multiple immunizations and by a different route.   
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CHAPTER 3.  LIVE VIRUS CHALLENGE STUDIES 
OF PASSIVELY IMMUNIZED PIGLETS 
Introduction 
PRRSV causes an extremely detrimental illness manifest by reproductive failure 
in pregnant sows and respiratory illness in young pigs.  Approximately $250 million is 
lost annually in nursery age pigs 48 72. 
The first humoral response to occur in a natural PRRSV infection of a pig is the 
production of anti-N antibodies 55, which have not been shown to be virus neutralizing 
(VN) antibodies and do not aid in viral clearance 101.  This initial antibody spike occurs 7-
9 days post infection (pi) and VN antibodies finally start to appear about 4 weeks pi  1 52 
55 101.  VN antibodies have been shown to have a protective role in reduction and 
prevention of viremia 74 88, but viremia has been shown to occur in the presence of VN 
antibodies 96.  Antibodies against GP5 have been found to be more neutralizing than anti-
GP4 antibodies and are the most effective VN antibodies 91.  This is supported by in vitro 
studies that have shown VN antibodies able to reduce PRRSV attachment to 
macrophages and inhibit virus internalization, since GP5 is involved in viral attachment.  
But attachment and internalization are only inhibited when homologous PRRSV strains 
and VN antibodies are used 32.   
Pigs naturally infected to PRRSV have an immune response that includes 
inducing VN antibody production 59 74.  Passive immunization of pregnant gilts 74 has 
demonstrated protection against reproductive failure and respiratory disease, as well as 
decreased transmission to naïve pigs.   
Another passive immunization study performed by Lopez et al.58 showed that 
administering VN antibodies against PRRSV to piglets protected against infection.  When 
VN titers reached 1:8 or greater there was a reduction in rectal temperatures and viral 
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load in tissues, and a faster clearance of viremia.  Although some immunized animals 
were not viremic, transmission to sentinel pigs still occurred as well as dissemination of 
PRRSV to tissues in challenged VN antibody immunized pigs.  A VN titer of 1:32 after 
passive immunization induced sterilizing immunity in 50% of the animals immunized.   
It was our hypothesis that piglets would be protected from PRRSV infection by 
passive immunization with immune plasma generated with only 3 PRRSV strains (see 
Chapter 2).  We hypothesized that producing the immune plasma with 3 strains of 
PRRSV with varying amounts and locations of glycans would provide protection against 
both homologous and heterologous challenges.   
The following reports the results from passive immunization of piglets against 
PRRSV and analysis of protection provided post infection.  Naïve sentinel piglets were 
also monitored and reported to determine the effect on transmission of PRRSV from pigs 
receiving either normal swine plasma or plasma from pigs hyperimmunized with 3 strains 
of PRRSV.     
Materials and Methods 
Source of animals 
All swine were received from a known PRRSV negative herd5.  Pigs were 
randomized using SAS statistical randomization (SAS institute, 1998).   
 Experiments to determine if pigs could be passively immunized against challenge 
by PRRSV 
In each of 4 experiments, 4 pigs received immune plasma and 4 pigs received 
normal plasma (see Table 7)and were challenged with either a homologous or 
                                                 
5 Ledger Swine Farm, Williamsburg, IA.  
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heterologous strain of PRRSV.  In addition, 2 sentinel pigs were added to each group 
subsequent to challenge in order to determine if passive immunization decreased the 
transmission of the virus to susceptible pigs.  In experiments 1 and 3 an additional group 
of 4 pigs were included that received immune plasma but were not challenged with 
PRRSV in order to determine the level of antibody passively transferred in the absence of 
challenge virus. 
 
Table 8.  Experimental design for challenge experiments of passively immunized piglets.   
 
*trt = Treatment 
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The polyvalent immune plasma used was from one gilt (Chapter 2) that was 
infected with 3 PRRSV strains at 3 separate times (HLV013, HLV093, HLV096, kindly 
provided by Dr. Kay Faaberg, University of Minnesota).  This immune plasma (α-
PRRSV) had an FFN titer of 1:1024 against HLV013 and an IDEXX HerdCheck® 
ELISA6 S/P ratio of 2.833 (nucleocapsid antibody) as determined by Iowa State 
University Veterinary diagnostic laboratory.  FFN titers of this plasma against HLV096 
and HLV092 were 1:512 and 1:256, respectively.  Pigs were weighed at -2 days post 
infection (dpi).  Pigs were immunized at day -1 and challenged with 2 ml of live PRRS 
virus intranasally, 1 ml/nare at day 0.  At day 3, sentinel pigs were moved to the room 
with the appropriate principle challenge group.  Pigs were bled at 0, 3, 7, 10, 14, and 21 
days post exposure (dpe) to the challenged group.  Blood was collected in serum-
separator vacutainer tube and centrifuged at 3500 RPM for 25 minutes.  Serum was 
aliquoted and stored at -80°C for virus titration, and at -20°C for serology.  FFN assay 
was run on serum from 24 hours post immunization (hpi) and 96 hpi (table).   
Challenged pigs were necropsied at 14 dpc and sentinel pigs were necropsied at 
21 dpe.  All pigs were sedated with Telazol/Xylazine/Ketamine, 1ml per 100 pounds 
bodyweight.  Each pig was administered 1 ml plus 1 ml per 10 pounds bodyweight of 
Sleepaway7 by intravenous injection.  Blood was collected from each pig and processed 
as described above.  Bronchial alveolar lavage (BAL) fluid  was collected at necropsy 66.  
Lungs were removed from each carcass and were severed from the trachea.  Dulbecco’s 
Modified Eagle’s Medium8 (DMEM) containing 0.5 mg/ml gentamicin was used to 
                                                 
6 IDEXX Labs, Portland, ME. 
7 Fort Dodge Laboratories, Fort Dodge, IA. 
8 Invitrogen Corporation, Carlsbad, CA. 
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lavage the lungs.  25 ml of DMEM was pipetted into the lungs.  The lungs were 
massaged and fluid was poured into a conical tube.  The BAL fluid was kept on ice and 
processed immediately after necropsy was completed.  BAL fluid was vortexed and 
dispensed into three, 1 ml aliquots and stored at -80oC.   
At necropsy, macroscopic lung lesions were scored as previously described 41. 
Each lung lobe was given a number to represent the percentage of each lobe affected by 
pneumonia.  Ten points, five dorsal and five ventral, were possible for each of the 
following:  right cranial (anterior) lobe, right middle lobe, cranial portion of the left 
cranial lobe and caudal portion of the left cranial lobe.  Five points were possible for the 
accessory lobe.  Fifteen points were assigned to the dorsal portion of each caudal lobe 
and 12.5 points were assigned to the ventral portion of each caudal lobe.  A total of 100 
points was possible to estimate the severity of visible pneumonia.  Lung scores were 
statistically analyzed using the Kruskal-Wallis step-wise comparison via SAS statistical 
analysis.   
Tissues sampled for histopathology were as follows: tonsil, heart, lymph nodes—
deep cervical, tracheobronchial, iliac and external inguinal, and lung—one section from 
each lung lobe.  Each tissue was blindly scored as previously described 42.  Lung lesions 
were assigned a numerical value between 0 and 5 as follows: 0 – No lesions, 1 – mild 
multifocal interstitial pneumonia (IP), 2 – mild diffuse IP, 3 – moderate multifocal IP, 4 – 
moderate diffuse IP, 5 – severe multifocal IP and 6 – severe diffuse IP.  Heart samples 
were given a value between 0 and 3 as follows: 0 - normal, 1 – mild multifocal 
lymphohistiocytic myocarditis (LM), 2 – moderate LM, 3 – severe LM.  Tonsil and 
lymph nodes were each give a score between 0 and 3 as follows: 0 – normal, 1 – mild 
lymphoid hyperplasia (LH), 2 - moderate LH, 3 – severe LH.  Scores were statistically 
analyzed using the Kruskal-Wallis step-wise comparison using SAS statistical analysis.     
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Experiment 1.  Homologous challenge with HLV013: intraperitoneal 
immunization with 0.6 ml/kg of immune plasma 
The first challenge experiment was conducted by passively immunizing pigs with 
1 intraperitoneal immunization.  Pigs were to be administered 1.0 ml/kg by injection of 
the intraperitoneal cavity with the appropriate plasma (NSP or α-PRRSV), but the weight 
of the pigs was underestimated, and the actual dosage was 0.6 ml/kg.  Pigs were 
challenged intranasally with 2 ml of HLV013 at 1.16 x 106 CCID50/ml, yielding a total 
innoculum dosage of 2.32 x 106 CCID50.  A group of non-challenged pigs receiving 
hyperimmune  plasma were included in this study. 
Experiment 2.  Homologous challenge with HLV013:   subcutaneous immunization 
with 2 ml/kg of immune plasma 
The first homologous challenge experiment was repeated with a higher dosage of 
immune plasma administered by a different route of administration.  In this experiment, 2 
ml/kg of the appropriate plasma (NSP or α-PRRSV) was administered by subcutaneous 
injection.  Pigs were challenged intranasally with 2 ml of HLV013 at 1.16 x 106 
CCID50/ml, yielding a total innoculum dosage of 2.32 x 106 CCID50.  Non-challenged 
pigs receiving immune plasma were not included in this experiment. 
Experiment 3. Homologous challenge with HLV096: subcutaneous immunization 
with 2 ml/kg of immune plasma 
In this experiment, 2 ml/kg of the appropriate plasma (NSP or α-PRRSV) was 
administered by subcutaneous injection.  Pigs were challenged intranasally with 2 ml of 
HLV096 at 7.91 x 106 CCID50/ml, yielding a total innoculum dosage of 1.58 x 107 
CCID50.  A group of non-challenged pigs receiving immune plasma were included in this 
study. 
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Experiment 4. Heterologous challenge with HLV092: subcutaneous immunization 
with 2 ml/kg of immune plasma 
In this experiment, 2 ml/kg of the appropriate plasma (NSP or α-PRRSV) was 
administered by subcutaneous injection.  Pigs were challenged intranasally with 5 ml of 
HLV092 at 7.91 x 103 CCID50/ml, yielding a total innoculum dosage of 4 x 104 CCID50.  
Non-challenged pigs receiving immune plasma were not included in this experiment 
Virus titration 
Serum samples from each pig were assayed for the presence of live virus by virus 
isolation as described previously 49.  Marc-145 cells were grown in 96-well flat-bottom 
plates for 3 days until monolayers were confluent.  100 ul of serum was serially diluted in 
10-fold dilutions out to 10-6 in tubes containing 900 ul of DMEM with 4% fetal calf 
serum, 200 ug/ml gentimicin, and 2.5 ug/ml Fungizone9.  Four replicates of each dilution 
were set up and incubated at 37°C with 5% CO2 for 8 days and examined for cytopathic 
effect (CPE).  A direct fluorescent antibody assay was also used, in which serum was 
incubated on cells for 3 days, fixed with cold 70% acetone/30% methanol.  A fluorescein-
conjugated anti-PRRSV monoclonal antibody, SDOW-17F10, was diluted 1:250 in 
1xPBS and 60 ul was aliquoted to each well, and incubated for 45 minutes at 37°C.  
Antibody was removed and wells were washed 3 times with 200 ul 1xPBS. Using an 
inverted fluorescent microscope, wells were examined for fluorescence.  Viral titers were 
calculated using the Reed-Muench calculation and log 10 conversions of each titer were 
performed prior to mean calculations.  Samples with no detectable virus were assigned a 
value of 1.  Mean titers were analyzed by t test using JMP.   
                                                 
9 Invitrogen Corporation, Carlsbad, CA. 
10 Rural Technologies Inc., Brookings, SD. 
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Serology 
Serum was submitted to the Iowa State University Veterinary diagnostic 
laboratory where the PRRS IDEXX HerdChek® PRRS ELISA was performed.  
Fluorescent focus neutralization (FFN) assay was performed by the South Dakota State 
University Animal Disease Research and Diagnostic Laboratory to determine the level of 
VN antibodies against the PRRSV strain used in challenge present in serum as described 
previously 98.  Briefly, serum was diluted in Eagle’s minimal essential medium 
supplemented with 2% horse serum.  Virus was added to each sample and allowed to 
incubate at 37°C for 1 hour.  Each dilution was then transferred to a 96-well plate in 
which confluent monolayers of MARC-145 cells were grown.  Plates were fixed with 
80% acetone after 24 hours.  FITC conjugated SDOW-17 was incubated in wells for 1 
hour to detect infected cells.  A dilution was considered positive when there was a 90% 
or greater reduction in the number of fluorescent foci. 
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Results 
Experiment 1 
All pigs administered α-PRRSV had positive VN antibody titers (≥1:4) at 24 
hours post immunization (hpi), 0 dpc (Figure 3), but none of the titers were greater than 
1:8.  At 3 dpc, titers in the α-PRRSV group ranged from <1:4 to 1:16.  
Although all challenged pigs had detectable virus at all time points, there was a 
delay in immune response in the α-PRRSV group, seroconverting for nucleocapsid 
antibody by 14 dpc while the NSP group seroconverted by 10 dpc (Table 7).  Viremia 
levels in the α-PRRSV group had a significantly lower mean titer than the NSP group at 3 
dpc (p=0.018) and 6 dpc (p=0.012), but not at dpc 10 (p=0.203) and 14 (p=0.857) (Table 
8).   
Macroscopic lung lesions were evaluated and recorded at necropsy (Table 9).  
The α-PRRSV group had a mean lung score of 17.8 which was not a statistically 
significant difference from the NSP group mean lung score of 35.7 (p=0.0571).  
Histopathologic lesions also were examined by Dr. Halbur and scored (Table 10).  The α-
PRRSV group did not have any significant difference in histopathologic lesions than the 
NSP group in lung, LN, tonsil, or heart (all p values ≥0.3). 
The sentinel pigs exposed to the challenged pigs were also evaluated for antibody, 
virus, macroscopic and hisopathologic lesions caused by PRRSV.  One of the sentinel 
pigs exposed to the α-PRRSV group never became viremic and never seroconverted for 
nucleocapsid antibody (Table 11).  The second pig of this group was viremic by 3 dpe 
and was positive for nucleocapsid antibody by 14 dpe as compared to 10 dpe for both of 
the sentinels exposed to NSP group.  Both sentinels in the latter group were also viremic 
beginning at 3 dpe.  Macroscopic lung lesions for the sentinels exposed to the α-PRRSV 
group had a mean of 2.0, compared with a 7.0 of the sentinels exposed to the NSP group 
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(no statistical significance, p value=0.667) (Table 12).  Histopathologic lesions did not 
have significant differences between the two groups of sentinels (all p values=1) (Table 
13).  As indicated by the data, transmission occurred in both groups of sentinel pigs, 
although transmission may have been delayed or viral exposure decreased.   
 Experiment 2 
At 1 dpi, VN antibody titers in the α-PRRSV group were higher than those 
achieved in experiment 1, and titers of the NSP group were negative (Figure 4).  The VN 
titers reached are of levels that have been shown to be protective in passive immunization 
58 74.  VN titers of the α-PRRSV group were maintained at 1:16 or higher and the NSP 
group remained negative.  With VN titers of at least 1:16, we would expect to see a 
decrease in or prevention of viremia in α-PRRSV immunized pigs58 74. 
Two of the four α-PRRSV pigs were positive for nuclecapsid antibody at 10 dpc 
and all 4 had serocnverted by 14 dpc.  One of the 4 NSP pigs had seroconverted for 
nuclecapsid antibody by 6 dpc, 3 seroconverted by 10 dpc and all 4 seroconverted by 14 
dpc (Table 14).  None of the α-PRRSV group were viremic at 3 dpc, as opposed to the 
NSP group in which all 4 pigs were viremic at 3 dpc, with a mean viremia level of 4.89 x 
105 CCID50/ml (p value=0.000125) (Table 15).  By 6 dpc, 3 of the 4 α-PRRSV pigs 
became viremic with a mean titer of 1.02 x 102 CCID50/ml, which was significantly 
different from the mean titer of the NSP pigs at 6 dpc, 3.67 x 105 CCID50/ml (p 
value=0.010).  By 10 dpc, the difference between the two groups was insignificant (p 
value=0.065) but by 14 dpc, there was a difference (p value=0.009) between the two 
groups.  The delay in viremia and significant difference in viremia levels at 3, 6, and 14 
dpc all correlate with the results of Lopez et al. 58, which showed 1:8 VN titers as 
preventing/decreasing viremia.   
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Macroscopic gross lung lesions scored for the α-PRRSV group were significantly 
different (p value=0.0286) from the NSP group with a mean score of 6.0 while the NSP 
group had a mean score of 26 (Table 16), indicating that some protection was provided 
by VN antibodies at levels that would be predictive of protection.  Histopathological 
lesions of tissues were scored but did not differ significantly (all p values ≥ 0.0857) 
between the α-PRRSV and the NSP groups (Table 17). 
Sentinel pigs exposed to α-PRRSV had a delay in viremia and immune response 
(Table 18).  This group was ELISA negative until 14 dpe when both pigs seroconverted, 
showing delay in transmission.  Both pigs became viremic at 7 dpe while sentinel pigs 
exposed to NSP pigs were viremic by 3 dpe.  The latter group of pigs was seropositive for 
nucleocapsid antibody by 10 dpe. 
Macroscopic lung lesions for the sentinels exposed to the α-PRRSV group had a 
mean score of 29 while the sentinels exposed to the NSP group had a mean of 10 (p 
value=0.333) (Table 19).  Histopathology scores did not differ significantly (all p values 
≥0.667) between the groups of sentinels (Table 20).   
Experiment 3 
VN antibody titers for the pigs administered α-PRRSV were present at 1 dpi, 
peaked with a mean inverse titer of 13.45 at 4 dpi and were maintained at an inverse titer 
of 8.00 (Figure 5), which is the VN titer shown to consistently block/delay viremia58.  Of 
the 4 pigs in this group, 3 never became viremic and only 1 had seroconverted for 
nucleocapsid antibody by 10 dpc, all 4 having seroconverted by 14 dpc (Table 21).  At 3 
dpc the NSP group had a mean titer of 1.55 x 104 CCID50/ml while the α-PRRSV group 
had no detectable virus (p value=5.85 x 10-5) (Table 22).  By 6 dpc, the NSP group had a 
mean titer of 8.70 x 103 while the α-PRRSV group was still negative (p value=0.004).  At 
10 and 14 dpc, the NSP group had mean titers of approximately 104 and 102, while the α-
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PRRSV group was not viremic at 10 dpc and only 1 pig was viremic at 14 dpc (both p 
values ≤ 0.015), indicating that the VN levels reached were effective at preventing 
viremia. 
Gross lung lesions were scored at necropsy, means of 11.00 and 17.25 for the α-
PRRSV group and the NSP group (p value= 0.971), respectively, indicating that, 
although viremia was prevented, dissemination and pathology was not prevented by 
immunization (Table 23).  Tissues were submitted for histopathology but could not be 
determined for this experiment due to misplacement of the slides and tissues. 
Sentinel pigs exposed to α-PRRSV pigs did not become viremic throughout the 
study (Table 24).  One of the sentinel pigs exposed to the NSP group became viremic by 
3 dpe and remained viremic, while the other pig was only viremic at 10 dpe.  Both pigs in 
this group were seropositive for nucleocapsid antibody by 14 dpe.   
Macroscopic lung lesions were different between the two groups with a mean 
score of 15.00 for the sentinels exposed to α-PRRSV pigs and a mean score of 63.00 for 
the sentinels exposed to NSP pigs (p value=0.333), which is not a statistically significant 
difference, due to the small sample size, but is an observed difference (Table 25).  
Unfortunately there is no histopathology data to support these results due to 
misplacement of these tissues as well.   
Experiment 4 
By 1 dpi, the group immunized with α-PRRSV had a mean inverse VN titer of 
9.51 (Figure 6) and none of the pigs had a VN level below 1:8 through 6 dpc. NSP 
administered pigs did not have inverse FFN titers greater than 4 throughout the study.  At 
3 dpc, 1 of 4 α-PRRSV pigs was viremic giving the group a mean titer of 1.26 x 101 
CCID50/ml as compared to the 4 of 4 NSP pigs that were viremic with a mean titer of 
1.07 x 105 CCID50/ml (Table 26) (p value=5.99 x 10-4).  By 6 dpc, all of the challenged 
 
 41
pigs were viremic and maintained viremia until necropsy.  At 6 dpc, the α-PRRSV pigs 
had mean viremia levels of 5.37 x 103 and the NSP pigs had a mean titer of 5.62 x 105 
CCID50/ml (Table 27) (p value=0.064).  At 10 dpc, the NSP pigs had mean viremia titer 
of 2.82 x 104 CCID50/ml while the α-PRRSV group had a mean titer of 1 x 103 
CCID50/ml (p value=0.010).  α-PRRSV pigs did not seroconvert for nucleocapsid 
antibody until necropsy at 14 dpc while 3 of the NSP pigs had seroconverted by 10 dpc.  
At necropsy, mean viremia levels for the α-PRRSV group and the NSP group were 1.26 x 
104 and 6.76 x 104 CCID50/ml, respectively (p value=0.021).   
Macroscopic lung lesions assessed at necropsy averaged 52.5 for the α-PRRSV 
group and 48.5 for the NSP group (p value=0.343) (Table 28).  Histopathological lesions 
did not differ greatly between the two groups (all p values≥0.486) (Table 29), but all of 
the pigs in both groups did have severe multifocal interstitial pneumonia.   
Sentinel pigs exposed to the NSP group became viremic by 3 dpe, while only 1 
pig exposed to the α-PRRSV group became viremic at 10 dpe and both pigs were only 
viremic at 21 dpe (Table 30).  Seroconversion for nucleocapsid antibody occurred by 10 
dpe in the sentinels exposed to the NSP group and only occurred in 1 of the sentinels 
exposed to the α-PRRSV group at 21 dpe, with 1 pig did not seroconvert at any time.   
Macroscopic lung lesions in sentinel pigs had a mean score of 23.5 for the group 
exposed to the α-PRRSV pigs and 38 for the group exposed to the NSP pigs (p 
value=0.667) (Table 31).  Histopathology showed an observed difference in interstitial 
pneumonia and myocarditis between the two groups, but due to small sample size, the 
statistical difference is not significant (all p values=0.333) (Table 32).   
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Figure 3.  Experiment 1.  Quantification of virus neutralizing antibody titers in either pigs 
passively immunized with antibody (α-PRRSV) or pigs administered normal plasma (NSP) 
and challenged with HLV013.   
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Table 9.  Experiment 1.  Presence of nucleocapsid antibody and PRRS virus determined 
in principle pigs either passively immunized with antibody to PRRSV (α-PRRSV) or 
administered normal swine plasma (NSP) and challenged with HLV013. 
 Number  of  pigs positive (4 pigs per group) 
 ELISA* VI** ELISA VI ELISA VI ELISA VI 
Days post 
challenge 
3 6 10 14 
α-PRRSV 0 4 0 4 0 4 4 4
NSP 0 4 0 4 4 4 3+ 3+
*Antibody in serum against nucleocapsid protein 
**PRRSV isolation from serum  
+One pig died on day 11 due to complications with bleeding unrelated to PRRSV 
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Table 11.  Experiment 1.  Gross lung lesions at necropsy of challenged pigs passively 
immunized with antibody to PRRSV (α-PRRSV) or pigs receiving normal swine plasma 
(NSP) and challenged with HLV013. Total possible score is 100 per pig. 
Treatment Group Pig # Total gross lung score Group Mean a
172 27 
176 11 
182 9 
α-PRRSV 
183 24 
17.8 
169 49 
174 NA 
180 29 
NSP 
181 29 
35.7 
Kruskal-Wallis step-wise comparison was performed (a p value=0.0571) 
 
 
Table 12.  Experiment 1.  Histopathological evaluation and score of interstitial 
pneumonia by microscopic lesions of challenged pigs immunized with either antibody to 
PRRSV (α-PRRSV) or pigs receiving normal swine plasma (NSP) and challenged with 
HLV013. 
Treatment 
Group 
Pig # Lung 
(0-6) 
Mean LN* 
(0-3) 
Mean Tonsil 
(0-3) 
Mean Heart 
(0-3) 
Mean 
172 4 2 2 0 
176 3 1 2 0 
182 3 2 2 1 
α-PRRSV 
 
183 4 
3.50 
2 
1.75 
2 
2.00 
1 
0.50 
169 5 2 2 1 
174 NA NA NA NA 
180 4 2 2 1 
NSP 
 
181 4 
4.33 
2 
2.00 
2 
2.00 
1 
1.00 
p value   0.286 1 1 0.429
*Lymph Nodes 
Kruskal-Wallis step-wise comparison was performed to calculate p values
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Table 13.  Experiment 1.  Detection of antibody and PRRSV in serum of sentinel pigs 
exposed to either pigs passively immunized with antibody to PRRSV (α-PRRSV) or 
exposed to pigs receiving normal swine plasma (NSP) and challenged with HLV013. 
*Antibody detected to nucleocapsid protein 
 Number of pigs positive (2 sentinel pigs per group) 
 ELISA* VI** ELISA VI ELISA VI ELISA VI ELISA VI
Days post 
exposure 
3 7 10 14 21 
α-PRRSV 0 1 0 1 0 1 1 1 1 0
NSP 0 2 0 2 2 2 2 2 2 2
**PRRSV isolation 
 
 
Table 14.  Experiment 1.  Gross lung lesions at necropsy of sentinel pigs exposed to 
either pigs passively immunized with antibody to PRRSV (α-PRRSV) or exposed to pigs 
receiving normal swine plasma (NSP) and challenged with HLV013.  Total possible 
score is 100 per pig. 
Treatment Group Pig # Total gross lung score Group Mean a
178 0 
α-PRRSV 179 4 2.0 
170 11 
NSP 175 3 7.0 
Kruskal-Wallis step-wise comparison was performed (a p value=0.667)
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Table 15.  Experiment 1.  Histopathological evaluation and score of interstitial 
pneumonia by microscopic lesions of sentinel pigs exposed to pigs immunized with either 
antibody to PRRSV (α-PRRSV) or pigs receiving normal swine plasma (NSP) and 
challenged with HLV013. 
Treatment 
Group 
Pig # Lung 
(0-6) 
Mean LN* 
(0-3) 
Mean Tonsil 
(0-3) 
Mean Heart 
(0-3) 
Mean 
178 1 1 1 0 α-PRRSV 
179 2 
1.50 
2 
1.50 
2 
1.50 
0 
0 
170 3 2 2 1 NSP 
175 1 
2.00 
2 
2.00 
2 
2.00 
0 
0.50 
p value  1 1 1 1
*Lymph Nodes 
Kruskal-Wallis step-wise comparison was performed to calculate p values 
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Figure 4.  Experiment 2.  Quantification of virus neutralizing antibody titers in either pigs 
passively immunized with antibody (α-PRRSV) or pigs administered normal plasma 
(NSP) and challenged with HLV013. 
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Table 16.  Experiment 2.  Antibody and live virus determined in principle pigs either 
passively immunized with antibody to PRRSV (α-PRRSV) or administered normal swine 
plasma (NSP) and challenged with HLV013. 
 Number  of  pigs positive (4 pigs per group) 
 ELISA* VI** ELISA VI ELISA VI ELISA VI 
Days post 
challenge 
3 6 10 14 
α-PRRSV 0 0 0 3 2 3 4 4
NSP 0 4 1 4 3 4 4 4
*Antibody detected to nucleocapsid protein 
**PRRSV isolation 
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Table 18.  Experiment 2.  Gross lung lesions at necropsy of challenged pigs passively 
immunized with antibody to PRRSV (α-PRRSV) or pigs receiving normal swine plasma 
(NSP) and challenged with HLV013.Total possible score is 100 per pig. 
Treatment Group Pig # Total gross lung score Group Meana
1252 6 
1257 11 
1267 6 
α-PRRSV 
 
1274 5 
6.0 
1251 30 
1255 34 
1264 22 
NSP 
1273 17 
26.0 
Kruskal-Wallis step-wise comparison was performed (a p value=0.029) 
 
Table 19.  Experiment 2.  Histopathological evaluation and score of interstitial 
pneumonia by microscopic lesions of challenged pigs immunized with either antibody to 
PRRSV (α-PRRSV) or pigs receiving normal swine plasma (NSP) and challenged with 
HLV013. 
Treatment 
Group 
Pig # Lung 
(0-6) 
Mean LN* 
(0-3) 
Mean Tonsil
(0-3) 
Mean Heart 
(0-3) 
Mean 
1252 1 2 2 0 
1257 4 2 2 1 
1267 4 1 3 1 
α-PRRSV 
 
1274 1 
2.50 
1 
1.50 
3 
2.50 
1 
0.75 
1251 5 1 1 3 
1255 5 1 1 2 
1264 4 2 2 2 
NSP 
 
1273 4 
4.50 
1 
1.25 
2 
1.25 
1 
2.00 
p value  0.130 1 0.089 0.114
*Lymph Nodes 
A Kruskal-Wallis step-wise comparison was performed to calculate p values 
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Table 20.  Experiment 2.  Detection of antibody and PRRSV in serum of sentinel pigs 
exposed to either pigs passively immunized with antibody to PRRSV (α-PRRSV) or 
exposed to pigs receiving normal swine plasma (NSP) and challenged with HLV013. 
 Number of pigs positive (2 sentinel pigs per group) 
 ELISA* VI** ELISA VI ELISA VI ELISA VI ELISA VI 
Days post 
exposure 
3 7 10 14 21 
α-PRRSV 0 0 0 2 0 2 2 2 2 2
NSP 0 2 0 2 2 2 2 2 2 1
*Antibody detected to nucleocapsid protein 
**PRRSV isolation 
 
Table 21.  Experiment 2.  Gross lung lesions at necropsy of sentinel pigs exposed to 
either pigs passively immunized with antibody to PRRSV (α-PRRSV) or exposed to pigs 
receiving normal swine plasma (NSP) and challenged with HLV013.Total possible score 
is 100 per pig. 
Treatment Group Pig # Total gross lung score Group Mean a
1258 42 
α-PRRSV 1265 16 29 
1253 8 
NSP 1256 12 10 
A Kruskal-Wallis step-wise comparison was performed (a p value=0.333) 
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Table 22.  Experiment 2.  Histopathological evaluation and score of interstitial 
pneumonia by microscopic lesions of sentinel pigs exposed to pigs immunized with either 
antibody to PRRSV (α-PRRSV) or pigs receiving normal swine plasma (NSP) and 
challenged with HLV013. 
Treatment 
Group 
Pig # 
Lung 
(0-6) 
Mean 
LN* 
(0-3) 
Mean Tonsil 
(0-3) 
Mean Heart 
(0-3) 
Mean 
1258 5 2 2 1 α-PRRSV 
1265 2 3.50 1 1.33 2 2.00 0 0.50 
1253 4 3 NA 1 NSP 
1256 2 3.00 2 2.50 2 2.00 0 0.50 
p value  1 0.667 1 1
*Lymph Nodes 
A Kruskal-Wallis step-wise comparison was performed to calculate p values 
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Figure 5.  Experiment 3.  Quantification of virus neutralizing antibody titers in either pigs 
assively immunized with antibody (α-PRRSV) or pigs administered normal plasma 
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Table 23.  Experiment 3. Antibody and live virus determined in principle pigs either 
passively immunized with antibody to PRRSV (α-PRRSV) or administered normal swine 
plasma (NSP) and challenged with HLV096.   
 Number  of  pigs positive (4 pigs per group) 
 ELISA* VI** ELISA VI ELISA VI ELISA VI 
Days post 
challenge 
3 6 10 14 
α-PRRSV 0 0 0 0 1 0 4 1 
NSP 0 4 0 4 1 4 3 4 
*Antibody detected to nucleocapsid protein 
**PRRSV isolation 
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Table 25.  Experiment 3.  Gross lung lesions at necropsy of challenged pigs passively 
immunized with antibody to PRRSV (α-PRRSV) or pigs receiving normal swine plasma 
(NSP) and challenged with HLV096.  Total possible score is 100 per pig. 
Treatment Group Pig # Total gross lung score Group Mean a
189 9 
194 24 
196 1 
α-PRRSV 
197 10 
11.00 
186 21 
190 1 
191 42 
NSP 
193 5 
17.25 
A Kruskal-Wallis step-wise comparison was performed (a p value=0.971) 
 
Table 26.  Experiment 3.  Detection of antibody and PRRSV in serum of sentinel pigs 
exposed to either pigs passively immunized with antibody to PRRSV (α-PRRSV) or 
exposed to pigs receiving normal swine plasma (NSP) and challenged with HLV096. 
 Number of pigs positive (2 sentinel pigs per group) 
 ELISA* VI** ELISA VI ELISA VI ELISA VI ELISA VI 
Days post 
exposure 
3 7 10 14 21 
α-PRRSV 0 0 0 0 0 0 0 0 0 0 
NSP 0 1 0 1 0 1 2 2 2 1 
*Antibody detected to nucleocapsid protein 
**PRRSV isolation 
 
Table 27.  Experiment 3.  Gross lung lesions at necropsy of sentinel pigs exposed to 
either pigs passively immunized with antibody to PRRSV (α-PRRSV) or exposed to pigs 
receiving normal swine plasma (NSP) and challenged with HLV096. Total possible score 
is 100 per pig. 
Treatment Group Pig # Total gross lung score Group Mean a
199 13 α-PRRSV 200 17 15.00 
187 60 NSP 198 66 63.00 
A Kruskal-Wallis step-wise comparison was performed (a p value=0.333) 
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Figure 6.  Experiment 4.  Quantification of virus neutralizing antibody titers in either pigs 
passively immunized with antibody (α-PRRSV) or pigs administered normal plasma 
(NSP) and challenged with HLV092. 
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Table 28.  Experiment 4. Antibody and live virus determined in principle pigs either 
passively immunized with antibody to PRRSV (α-PRRSV) or administered normal swine 
plasma (NSP) and challenged with HLV092.   
 Number  of  pigs positive (4 pigs per group) 
 ELISA* VI** ELISA VI ELISA VI ELISA VI 
Days post 
challenge 
3 6 10 14 
α-PRRSV 0 1 0 4 0 4 4 4 
NSP 0 4 0 4 3 4 4 4 
*Antibody detected to nucleocapsid protein 
**PRRSV isolation 
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Table 30.  Experiment 4.  Gross lung lesions at necropsy of challenged pigs passively 
immunized with antibody to PRRSV (α-PRRSV) or pigs receiving normal swine plasma 
(NSP) and challenged with HLV092.  Total possible score is 100 per pig.
Treatment Group Pig # Total gross lung score Group Mean a
1915 59 
1926 52 
1937 48 
α-PRRSV 
1942 51 
52.5 
1902 49 
1913 47 
1935 45 
NSP 
1936 53 
48.5 
A Kruskal-Wallis step-wise comparison was performed (a p value=0.343) 
 
 
Table 31.  Experiment 4.  Histopathological evaluation and score of interstitial 
pneumonia by microscopic lesions of challenged pigs immunized with either antibody to 
PRRSV (α-PRRSV) or pigs receiving normal swine plasma (NSP) and challenged with 
HLV092. 
Treatment 
Group 
Pig # Lung 
(0-6) 
Mean LN* 
(0-3) 
Mean Tonsil 
(0-3) 
Mean Heart 
(0-3) 
Mean 
1915 5 1 1 2 
1926 5 2 2 2 
1937 5 2 2 2 
α-PRRSV 
 
1942 5 
5.00 
2 
1.75 
2 
1.75 
1 
1.75 
1902 5 1 2 2 
1913 5 2 2 1 
1935 5 2 2 1 
NSP 
 
1936 5 
5.00 
2 
1.75 
2 
2.00 
1 
1.25 
p value  1 1 1 0.486
*Lymph nodes 
A Kruskal-Wallis step-wise comparison was performed to calculate p values 
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Table 32.  Experiment 4.  Detection of antibody and PRRSV in serum of sentinel pigs 
exposed to either pigs passively immunized with antibody to PRRSV (α-PRRSV) or 
exposed to pigs receiving normal swine plasma (NSP) and challenged with HLV092. 
 Number of pigs positive (2 sentinel pigs per group) 
 ELISA* VI** ELISA VI ELISA VI ELISA VI ELISA VI 
Days post 
exposure 
3 7 10 14 21 
α-PRRSV 0 0 0 0 0 1 0 1 1 2 
NSP 0 2 0 2 2 2 2 2 2 2 
*Antibody detected to nucleocapsid protein 
**PRRSV isolation 
 
 
Table 33.  Experiment 4.  Gross lung lesions at necropsy of sentinel pigs exposed to 
either pigs passively immunized with antibody to PRRSV (α-PRRSV) or exposed to pigs 
receiving normal swine plasma (NSP) and challenged with HLV096. Total possible score 
is 100 per pig. 
Treatment Group Pig # Total gross lung score Group Mean a
1938 8 α-PRRSV 1939 39 23.5 
1901 49 NSP 1934 27 38.0 
A Kruskal-Wallis step-wise comparison was performed (a p value=0.667) 
 
 
Table 34.  Experiment 4.  Histopathological evaluation and score of interstitial 
pneumonia by microscopic lesions of sentinel pigs exposed to pigs immunized with either 
antibody to PRRSV (α-PRRSV) or pigs receiving normal swine plasma (NSP) and 
challenged with HLV092. 
Treatment 
Group 
Pig # 
Lung 
(0-6) 
Mean 
LN* 
(0-3) 
Mean Tonsil 
(0-3) 
Mean Heart 
(0-3) 
Mean 
1938 1 1 1 0 α-PRRSV 
1939 3 2.0 1 1.0 1 1.0 0 0 
1901 6 2 2 2 NSP 
1934 5 5.5 2 2.0 2 2.0 2 2.0 
p value  0.333 0.333 0.333 0.333
*Lymph nodes 
A Kruskal-Wallis step-wise comparison was performed to calculate p values 
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Discussion  
Although pigs in experiment 1 did not have a high level of passively acquired 
antibody, protection was still provided.  Pigs in experiment 2 showed a significant 
decrease in viremia levels at all time points except for 10 dpc.  Protection was also shown 
in the form of less severe interstitial pneumonia in the immunized pigs and in the 
sentinels exposed to this group.  There was also a delay in transmission to the sentinel 
pigs exposed to the immunized group as compared with the sentinels exposed to the NSP 
treated pigs.  These results are correlative to that of Lopez et al.58, supporting the 
evidence that low levels of VN antibody can delay viremia.  Due to the small sample size 
and the design of the statistical analysis, the difference in lung score lesions of the 
sentinel pigs was not significant, but is an observed difference.   
In experiment 3 the immunized pigs had no detectable viremia, except for 1 pig at 
necropsy that had an extremely low level of virus.  Gross lung lesions did not differ 
greatly between the two groups but both groups had low macroscopic lung lesion scores, 
indicating the virus may not have been virulent.  The sentinel pigs exposed to the α-
PRRSV immunized group did not become viremic nor did they seroconvert at any time 
point, indicating that transmission did not occur.  Macroscopic lung lesions were different 
between the two groups, although not determined statistically significant due to sample 
size.  This numerical difference in macroscopic lung lesions and the lack of viremia in 
sentinels indicates that transmission was prevented when sentinels were exposed to α-
PRRSV immunized pigs, which was not shown by Lopez et al58.  The sentinel pigs 
exposed to the NSP group had a mean macroscopic lung score of 63, indicating their 
exposure dose was high and the virus may have become more virulent by passage 
through the NSP pigs.  
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Experiment 4 showed protection in the form of decreased viremia in the 
immunized pigs, which was a significant difference at all time points except at 6 dpc, 
indicating that the VN levels were high enough to delay viremia.  Macroscopic lung 
lesions were very high in both the immunized and non-immunized pigs, possibly due to 
the virulence of the challenge strain or the increased volume of challenge virus.  The 
sentinel pigs exposed to the α-PRRSV group demonstrated delay in transmission, but 
minimal protection based on macroscopic and histopathologic lesions.  In experiment 4, a 
greater inoculum dose was utilized due to low titer of the virus.     
Each of the challenge studies demonstrated some level of protection provided by 
passive immunization with immune plasma.  Protection was shown in the form of delay 
in viremia, level of viremia, decrease in lung lesions, or delay and/or lack of transmission 
to naïve sentinels.  The greatest level of protection was demonstrated in homologous 
challenge with HLV096 (Experiment 3) even though the VN antibody titers were highest 
in Experiment 2 against HLV013.  According to published results by Lopez et al. 58, the 
high VN levels achieved by passive immunization of pigs in experiment 2 would be 
expected to result in “sterilizing immunity” of 50% of the animals, which was not shown, 
as 75% of the animals became viremic by 6 dpc.  But sterilizing immunity was 
demonstrated in experiment 3 pigs, in which viremia was prevented in the immunized 
pigs and the sentinels exposed to these pigs, even though the VN levels in the passively 
immunized pigs were not at sterilizing levels of 1:32 as indicated by Lopez et al.   
In vitro studies have shown VN antibodies against GP5 are able to reduce PRRSV 
attachment to macrophages and inhibit virus neutralization32.  But attachment and 
internalization are only inhibited when homologous PRRSV strains and VN antibodies 
are used.  Future research could include in vitro inhibition studies to determine if the 
immune plasma used in passive studies is capable of completely inhibiting attachment 
and internalization of both homologous and heterologous PRRSV strains.  
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It is interesting that the HLV096 challenge strain (experiment 3) and the 
heterologous challenge strain (HLV092, experiment 4) only differ by 4 amino acids in the 
21-60 amino acid range of GP5 and have the same glycan pattern (see appendix).  The 
VN antibody levels are very similar between experiments 3 and 4 and yet the level of 
protection was greater in experiment 3.  It would be beneficial to repeat the study with 
the same volumes of HLV096 and HLV092 challenge virus to determine if this 
difference in protection was due to an increase in volume of challenge virus.  It would 
also be interesting to repeat this experiment with other heterologous strains with varying 
levels of relatedness to the strains used in immune plasma production.  The outcome 
would aid in determining if the decrease in protection is due to the immune plasma 
lacking antibody specific to the challenge strain or if it is due to the relatedness of the 
challenge virus to the virus used in producing the immune plasma.   
Although we did demonstrate protection, we were unable to show more protection 
than previous studies58.  Future research could include generating immune plasma with 
the same PRRSV strains, but in a different infection order, as well as generating plasma 
with different PRRSV strains.  It would be interesting to determine if antibodies to less 
glycosylated strains are more effective when initially produced, or being induced after 
multiple infections.  Additional research including increased dosage of passive antibody 
would also be beneficial.  If we had the opportunity and resources to repeat these studies, 
it would be interesting to monitor the antibody levels for a longer period of time post-
challenge.   
Maternally derived antibodies against PRRSV have shown to protect against 
PRRSV exposure in piglets24.  But there is no data evaluating immune activity in such 
piglets.  Research has shown that maternally derived antibodies against certain viruses 
can provide complete protection in offspring, but also completely inhibit an immune 
response in the offspring when exposed to the virus.  This is the case with swine 
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influenza54.  But maternal antibodies against Bovine Viral Diarrhea virus (BVDV) 
provide protection while allowing the offspring to develop an immune response36.  It 
would be of great value to determine if an immune response in passively immunized 
piglets is inhibited by passive antibodies.  This could be done by including a second 
challenge in the previously described experimental design to see if an immune response 
was induced in passively immunized piglets when exposed to live PRRSV a first time.  If 
an immune response was induced during first infection/exposure to the virus while 
preventing clinical symptoms, this would be an ideal strategy for farmers.  This would 
allow a method to immediately protect piglets against PRRSV infection and induce an 
immune response to protect them against future PRRSV infection.    
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CHAPTER 4.  GENERAL CONCLUSIONS 
Results from immune plasma production indicated that multiple infections of 
naïve gilts generated significantly high VN titers.  Although it was not determined 
whether number of infections, number of strains used, or time post infection had the 
greatest impact on VN antibody production, it was shown that the highest VN levels 
against heterologous strains were produced by pigs infected with more than 1 PRRSV 
strain.  Although some heterologous VN titers were generated, VN titers against Lelystad 
Virus and SD01-08 (European-like) were never produced in 19 of 20 pigs (one pig had a 
VN titer of 1:8 at 135 dpi).   
Immune plasma was produced with sufficient VN levels that could be passively 
administered to naïve piglets.  Passive immunization was demonstrated in both the 
antibody decay study and the antibody maintenance study, indicating VN levels that have 
previously been shown to significantly reduce viremia in immunized pigs55 74 could be 
reached via subcutaneous or intraperitoneal immunization.    Although antibody level 
endpoints were never determined, we did show that the VN levels remain at levels 
considered protective for at least 13 days.  This could be very beneficial in movement of 
pigs from farrowing to nursery barns, as not all pigs are weaned at exactly the same time. 
The infection of gilts with two different strains (Group 2) or with three different 
strains (Group 3) of PRRSV resulted in high titer neutralizing antibodies to all North 
American strains evaluated but no cross reactivity to the European strains in 7 of 8 pigs 
(Tables 5 and 6).  It is interesting to note that strain HLV093 (used as the second 
infecting strain in both Groups 3 and 4) has a unique glycosylation pattern as compared 
to all other strains.  Strain HLV093 lacks a glycan at AA position 44 which is centered in 
the neutralizing epitope region of GP5 75 81.  It is tempting to speculate that the absence of 
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this glycan allows for the inducement of cross reacting antibodies to the other NA strains 
tested by FFN.  However, further work is necessary to confirm this statement. 
The research reported herein these chapters have shown the ability to generate 
high VN antibody titers in naïve gilts.  Passively administering this immune plasma has 
provided some level of protection against PRRSV.   
Each of the challenge studies described in chapter 3, demonstrated some level of 
protection provided by passive immunization with high titer VN antibodies.  Protection 
was shown by delay in viremia, level of viremia, decrease in macroscopic and 
microscopic lung lesions, or delay and/or lack of transmission to naïve sentinels.  The 
greatest level of protection was demonstrated in homologous challenge with HLV096 
(Experiment 3) even though the VN antibody titers were highest in Experiment 2 against 
HLV013.  Recent publication by Lopez et al.58 would predict that the high VN levels 
achieved by passive immunization of pigs in experiment 2 would result in “sterilizing 
immunity” of 50% of the animals, which was not shown (75% of the animals became 
viremic by 6 dpc).  However, sterilizing immunity was demonstrated in experiment 3 
pigs, in which viremia was prevented in the immunized pigs and the sentinels exposed to 
these pigs, even though the VN levels in the passively immunized pigs were not at 
sterilizing levels of 1:32 as determined by Lopez et al58.   
Maternally derived antibodies against PRRSV have shown to protect against 
PRRSV exposure in piglets24.  But there is no data evaluating immune activity in such 
piglets.  Research has shown that maternally derived antibodies against certain viruses 
can provide complete protection in offspring, but also completely inhibit an immune 
response in the offspring when exposed to the virus.  This is the case with swine 
influenza54.  But maternal antibodies against Bovine Viral Diarrhea virus (BVDV) 
provide protection while allowing the offspring to develop an immune response36.  It 
would be of great value to determine if an immune response in passively immunized 
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piglets is inhibited by passive antibodies.  This could be done by including a second 
challenge in the previously described experimental design to see if an immune response 
was induced in passively immunized piglets when exposed to live PRRSV a first time.  If 
an immune response was induced during first infection/exposure to the virus while 
preventing clinical symptoms, this would be an ideal strategy for farmers.  This would 
allow a method to immediately protect piglets against PRRSV infection and induce an 
immune response to protect them against future PRRSV infection.  
Although previous passive immunization studies have shown sterilizing immunity 
in some young piglets58 and prevention of reproductive failure74, our results were 
different due to several factors.  In relation to Osorio’s work with pregnant gilts, the age 
of the pigs may have an impact on the resulting protection74.  Because older pigs have a 
more developed immune response, this in conjunction with passively administered VN 
antibodies may work together to prevent infection.  Future work in our laboratory could 
include passive immunization studies with pregnant gilts to determine if the immune 
plasma we produced is as effective.   
Because the pork industry is so negatively affected by PRRSV, much research is 
needed to find a solution.  Despite a passive immunization strategy only being a 
temporary solution (since it would not induce a natural immune response in the pigs 
immunized), if protection against multiple PRRSV strains could be shown, passive 
immunization could be an extremely beneficial option for the pork industry.     
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